Vol. 3 Issue 1 Part A

Objectives: To earmark clinical superiority of either of the drugs given prophylactically in managing intraocular pressure spikes following Nd:YAG laser posterior capsulotomy.

Method: The present study was conducted on 100 patients, who had developed posterior capsule opacification following successful cataract surgery with intraocular lens implantation and underwent Nd:YAG laser posterior capsulotomy in the Outpatient Department of Ophthalmology, RMCH.

Results: In Apraclonidine group, pressure differences with control group were evident at 3 hours (ΔP₃) & at 24 hours (ΔP₂₄) that were highly statistically significant; (p=0.0078 & 0.0045 for ΔP₃ & ΔP₂₄ respectively). The same were not significantly different (p> 0.05) at 1 hour or day 7 following laser application. The Briminodine group demonstrated significant differences in pressure fluctuations compared with control group at all recorded times with maximum variation noted at 3 hours post capsulotomy (p=0.000015).

Conclusion: It was concluded Both Apraclonidine & Briminodine are found useful drug interventions in laser therapy, but Briminodine clearly scores over former in dampening the IOP rise.